Enfortumab Vedotin vs Osimertinib
Enfortumab Vedotin vs Osimertinib: Overview
This comparison examines the pharmacological differences between Enfortumab Vedotin and Osimertinib.
Mechanism of Action
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Pharmacokinetics
Half-life: Osimertinib — 48 hours.
Chemical Properties
Molecular Formula: Osimertinib — C28H33N7O2.
Molecular Weight: Osimertinib — 499.6050 g/mol.
Type: Enfortumab Vedotin — Antibody drug conjugate; Osimertinib — Small molecule.